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S232 Poster Session I0%-43%) and 10% (95%CI, 0%-23%) for MRD and CB, respec-
tively (p5 0.6)
Conclusion:The use of allogeneic HSCTwith RIC provides favor-
able disease outcomes in older AML patients in CR1. CB should be
considered as an alternative donor source in patients with no MRD
donor available.199
SYNERGISTIC CYTOTOXICITY OF CLOFARABINE, FLUDARABINE AND BU-
SULFAN: RELEVANCE TO MYELOABLATIVE THERAPY
Valdez, B.C.1, Li, Y.1, Murray, D.2, Champlin, R.E.1, Andersson, B.S.1
1UT M.D. Anderson Cancer Center, Houston, TX; 2Cross Cancer Insti-
tute, Edmonton, AB, Canada
Clofarabine (Clo) and Fludarabine (Flu) are purine nucleoside an-
alogues (NA) with antileukemia activity. Their synergistic cytotoxic-
ity in the absence or presence of DNA alkylating drug Busulfan (Bu)
has not been reported. To determine the efficacy and synergism of
these three drugs in Bu-resistant AML cell line (KBM3/Bu2506),
various combinations were analyzed for their cytotoxicity. Clo, Flu
and Bu have IC50 values of 0.03 mM, 1.22 mM and 126 mM, respec-
tively. Combination of 0.01 mM Clo and 0.2 mM Flu resulted in
84% cell survival after 4 d; addition of 40 mMBu to this combination
decreased cell survival to 59% suggesting synergism. Cell cycle anal-
ysis after 2-day exposure of cells to either 0.015 mM Clo or 0.6 mM
Flu showed 6% cells in sub-G1. When combined at the same con-
centrations, 20% cells were in sub-G1 and 5% were TUNEL-posi-
tive. Addition of 80 mM Bu to this combination increased sub-G1
and TUNEL-positive cells to 35% and 15%, respectively. These re-
sults suggest synergistic efficacy of Clo and Flu which further im-
proves with addition of Bu. Immunoblot analysis of cells exposed
to 0.015 mM Clo + 0.6 mM Flu resulted in significant cleavage of
PARP1 and increased g-H2AX compared with exposure to either
NA alone; addition of 80 mM Bu increased the effects two-fold.
These results suggest drug-mediated induction of DNA damage re-
sponse and apoptosis. Inhibition of ribonucleotide reductase (RNR)
with 100 mMhydroxyurea (HU) was also synergistic with Clo or Flu.
The effects of [Clo + Flu], [Clo +HU] and [Flu +HU] were reversed
by 100 mM cytidine. These data support self-potentiation of [Clo + -
Flu] combination as a possible mechanism of their synergistic cyto-
toxicity where both NA inhibit RNR, decrease deoxynucleotide
synthesis and make more deoxycytidine kinase available to phos-
phorylate and activate Clo and Flu. This mechanism may result in
enhanced incorporation of Clo and Flu during DNA synthesis.
[Clo + Flu] combination also resulted in more significant methyla-
tion of histone H3 suggesting increased chromatin remodeling
which possibly exposed more DNA to Bu-mediated cross-linking
and explains the observed synergism of [Clo + Flu + Bu]. This model
is consistent with a dramatic increase in the level of g-H2AX, an in-
dicator of DNA damage, when Bu was added to [Clo + Flu] combi-
nation. Overall, our results suggest that addition of [Clo + Flu]
might synergistically improve the cytoreductive efficacy of Bu-based
pre-transplant regimen in myeloid leukemia patients.200
EFFECTS OF CHANGES IN CONDITIONING REGIMEN AND SUPPORTIVE
CARE ON OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
Abello, V., Rosales, C., Pedraza, E., Linares, A., Esguerra,H., Rosales,M.,
Figueroa, J. Clınica de Marly, Bogota, Colombia
As in all centers around de world, transplant strategies have change
in our center over the time.Here we report the results of a single cen-
ter, retrospective analysis of outcomes in patients with AML treated
with high dose therapy and allo-SCT, from 1994 to 2009, comparing
patients treated before and after 2005whenwe changed conditioning
regimen for AML to Fludarabine-Busulfan and implemented sup-
portive measures as Levofloxacine as prophylaxis, CMV pre-emptive
strategy, and EICH prophylaxis with Micofenolate (MMF).
Since 1994, 59 LMA patients have been treated, 57 received pe-
ripheral blood HLA identical related grafts and 2 patients receivedUR cord blood transplants. As conditioning, 3 patients received
RIC and 56 full intensity conditioning (BuCy 25 – BuFlu 23 – other
8). Only 3 (5%) had high risk cytogenetics at diagnosis but 40%were
considered of high risk at transplantation (44% for BuCy and 39%
for BuFlu). Table 1. Describes patient characteristics and outcomes
for all patients and BuCy vs BuFlu groups. Of note BuCy and BuFlu
groups are very similar except for CMV positivity 56 vs 78% and
time from diagnosis to transplant 24 months (2.3-167) vs 14.5
(2.13-33).
BuFlu patients received routine Levofloxacine prophylaxis (78%
vs 0% BuCy group), GVHD mainly with Cs-MMF (69% vs BuCy
group 28%) and were treated for CMV in a preemptive strategy.
As shown in table toxicity related to the procedure was greatly re-
duced with BuFlu strategy, having a shorter hospital stay, less fever,
diarrhea, requiring less antibiotics and transfusion support. There
were no toxic deads in BuFlu group.
For BuCy group, at a median follow-up of 12.8 months (range 0.5-
118.), 9 patients are alive in CR (36%), 4 were lost for follow-up
(16%) and 12 died (48%). 4 patients (16%) died before day 100 of
transplant related causes. Main cause of death was relapse in 7
(58.3%).
For BuFlu group, at a median follow-up of 7 months (range 1-40),
13 (56.5%) are alive in CR, 1 is alive in relapse (4.3%) and 9 died
(39.1%). No patient died before day 100. Relapse has been the
main cause of dead so far, 4 (33.3%); followed by pulmonary compli-
cations, 3 (25%) and EICH related complications 2 (16.7%).
This retrospective analysis suggest benefit of Bu-Flu and newer
supportive strategies in early toxicity related to HLA familial allo-
SCT over BuCy. Longer follow-up and greater numbers of patients
are needed to draw conclusions about its significance in long-term
survival.
Patient characteristics and outcomes
All (N 59) BuCy (N. 25) Bu-Flu (N. 23)Gender (M/F) 32/27 12/13 14/11
Age 34 (6-63) 34.9 (6-55) 33.8 (10-61)
# Previus cycles 4.67 (1-16) 4.5 (1-16) 4.7 (1-9)
CD341x10-6/kg 3.3 (0.3-11.1) 2.9 (1.1-8) 2.9 (0.8-11)
Hospital stay 32.1 (21-80) 34.7 (22-54) 27.3 (22-40)
% weigth loss 5 (-3.4 – 13.6) 6 (0-12.9) 3.7 (-3.4-12.1)
Neutrophyls graft 13 (6-43) 14 (9-43) 11 (6-14)
Fever (days) 4.1 (0-22) 4.8 (1-20) 1.9 (0-5)
Diarrhea (days) 3.9 (0-21) 5 (0-15) 2.9 (0-21)
TPN (days-% patients) 6.2 (0-25)-61% 8.3 (0-21)-72% 3.1 (0-10)-48%
Antibiotic days 32.4 (0-127) 42.56 (12-127) 17 (0-49)
RBC transfusion 1.8 (0-28) 1.92 (0-14) 0.6 (0-5)
PLT transfusion 4.9 (0-35) 6.5 (1-27) 1.4 (0-18)
Mortality\100 days 6.7% 16% 0%201
UNRELATED DONOR REDUCED-INTENSITY STEM CELL TRANSPLANTA-
TION IS A PROMISING TREATMENT OPTION FOR ELDERLY PATIENTS
WITH BLASTIC PLASMOCYTOID DENDRITIC CELL NEOPLASM (BPDC)
Dietrich, S.1, Hegenbart, U.1, Schmitt, T.1, Martens, U.2, Ho, A.D.1,
Dreger, P.1 1University of Heidelberg, Heidelberg, Germany; 2SLK-Kli-
niken, Heilbronn, Germany
Blastic plasmacytoid dendritic cell neoplasm (BPDC), formerly
known as blastic NK cell lymphoma, is a rare hematopoietic malignancy
preferentially involving skin, bone marrow and lymph nodes. The
overall prognosis of BPDC is dismal. Most patients show an initial
response to acute leukemia-like chemotherapy, but relapses with
subsequent drug resistance occur in virtually all patients resulting
in a median overall survival of only 9-13 months. However, anec-
dotal long-term remissions have been reported in young patients
who received early myeloablative allogeneic stem cell transplanta-
tion (alloSCT). As the median age at diagnosis is above 60 years,
most patients at risk will not be eligible for myeloablative alloSCT.
Here we present our experience with reduced-intensity conditioning
(RIC) alloSCT from unrelated donors in elderly patients with
BPDC.
Patient # Age/sex Involvement Pretreatment Status at alloSCT Conditioning Donor Outcome
1 64/m Skin ALL-like, HD-Mtx CR2 Flu-Bu-Cy-ATG MMUD 8/10 Chronic GVHD, alive in CR, 441 mo
2 67/m Skin, BM ALL-like, Gemcitabine Refractory Flu-Bu-Cy-ATG MMUD 9/10 Dead (REL 71 mo)
3 69/m Skin, BM AML-like Refractory Flu-Treosulfan-ATG MUD 10/10 Alive in CR 71 mo
4 55/f Skin ALL-like CR1 Flu-Bu-Cy-ATG MUD 10/10 Alive in CR 51 mo
Poster Session I S233Six consecutive patients with BPDC have been treated at our insti-
tution between 2004 and 2008. All patients responded to acute leu-
kemia-like induction therapy. Whereas two patients were ineligible
for alloSCT due to comorbidity and experienced rapid relapse, 4 pa-
tients proceeded to RIC alloSCT as part of first-line (n5 1) or sal-
vage treatment (n5 3) (Table). Median age was 66 (55-69) years.
Two patients had active disease at the time of alloSCT. Condition-
ing was based on submyeloablative doses of busulfan or treosulfan
with fludarabine and ATG, followed by transplantation of unmanip-
ulated peripheral blood stem cell grafts obtained from matched or
mismatched unrelated donors. Three patients live progression-free
44, 7 and 5months post alloSCT, one patient relapsed 7months after
SCT and died soon thereafter.
We conclude that RIC SCT from unrelated donors is feasible in
elderly patients with BPDC and might provide curative potential
in this otherwise incurable disease. Prospective analyses of RIC al-
loSCT in BPDC are warranted.202
OUTCOME OF ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEU-
KEMIA (EALL) WITH CHEMOTHERAPY: THE VANCOUVER EXPERIENCE
Tantiworawit, A., Barnett, M.J., Forrest, D.L., Hogge, D.E.,
Nantel, S.H., Narayanan, S., Nevill, T.J., Power, M.M.,
Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J.,
Toze, C.L., Abou Mourad, Y.R. University of British Columbia, Vancou-
ver, BC, Canada
Introduction: Age remains probably the most important prognos-
tic factor in acute lymphoblastic leukemia (ALL). Adults with ALL
have poor outcome with chemotherapy when compared to chil-
dren; as age increases overall survival (OS) continuously declines.
Elderly ALL (EALL) patients (pts) have the worst outcome with
chemotherapy. Despite good initial response to induction chemo-
therapy, relapse rate (RR) is high and most pts will succumb to
their disease. Few studies have addressed the outcome of EALL
with chemotherapy.
Patients and Methods: Retrospective analysis of 32 EALL pts
treated with chemotherapy at the L/BMT program of BC, Canada
between 1989-2008. EALL was defined by age $60 years. Cytoge-
netics was available on 28(87.5%) pts. All pts received a consistent in-
duction/consolidation and maintenance chemotherapy as per our
modified ALL89-01 protocol. Complete remission (CR), Event
free survival (EFS) and OS were analyzed.
Results:Betwen1989-2008, 32 pts (8.7% of adult ALL) were EALL,
median age 66.0(60.1-76.1) years, 50% males. Median wbc count
was 7.4(0.8-43) x109/L. 7/32(28%) were Ph+. Only one pt had
CNS involvement. All pts received a consistent induction with dau-
norubicin, vincristine and prednisone. 27/32(84.4%) achieved CR.
18/27(66.7%) of pts. who achieved CR received phase II induction
consisting of cyclophosphamide, cytarabine, and mercaptopurine.
Consolidation chemotherapy was given in 17/27 (62.9%), in 15/
17(88.2%) consisted of 1-2 cycle of cytarabine and tenoposide. 6
pts also received modified intensification with vincristine, daunoru-
bicin, cyclophosphamide. 4 pts received tyrosine kinase inhibitor
(TKI) with consolidation. 2 pts received other chemotherapy. Main-
tenance with methotrexate and mercaptopurine were given in 20 pts
which include 4 pts who did not receive consolidation. 23/27(85.2%)
pts who achieved CR had relapse. Median time to relapse from diag-
nosis is 240(112-1317) days. Median EFS and OS are 313(0-1317)
and 489(38-1770) days, respectively. Cause of death was disease pro-
gression in 25/27 (92.6%). 6/7(85%) of Ph+ pts received combina-tion chemotherapy with TKI. 3-year OS for the whole group was
26%, 36% for Ph+ pts and 23% for Ph- ALL.
Conclusions: EALL have poor outcome with chemotherapy. De-
spite the excellent CR rate with chemotherapy (84.4%), RR remains
high (85.2%) and most patients (96.2%) die secondary to DP. In the
TKI’s era, EALL with Ph+ disease relatively fair better than Ph-
EALL.
3-year disease free survival and over all survival
All Patient Ph1 group Ph- group P valueNumber 32 7 25
3-year DFS 15% 0% 19% 0.20
3-year-OS 26% 36% 23% 0.81LYMPHOMA/MULTIPLE MYELOMA
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH
REDUCED-INTENSITY CONDITIONING IN PATIENTS WITH REFRACTORY
AND RELAPSING MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP
Shimoni, A.1, Hardan, I.1, Ayuk, F.2, Schilling, G.2, Atanackovic, D.2,
Zeller, W.2, Shem-Tov, N.1, Rand, A.1, Yerushalmi, R.1, Zander, A.2,
Kro¨ger, N.2, Nagler, A.1 1Chaim Sheba Medical Center, Tel-Hashomer,
Israel; 2University Hospital Hamburg, Hamburg, Germany
Allogeneic SCTwithmyeloablative conditioning is potentially cu-
rative therapy for multiple myeloma (MM), but is associated with ex-
cessively high rates of non-relapse mortality (NRM). Reduced-
intensity conditioning (RIC) allows reduction of NRM but relapse
rate is increased. The role and timing of allogeneic SCT during
the disease course are controversial. There is only limited data on
the long-term outcome of RIC in the relapsing/refractory setting.
We retrospective analyzed SCT outcomes in 50 patients (pts) given
RIC for relapsing/refractory MM, between the years 2000-2004,
from related (n5 27) or unrelated (n5 23) donors. The median
age was 53 years (32-64). This was a relatively heavily pretreated
group, amedian of 3 years from diagnosis (0.5-14 years). Forty-seven
pts failed one (n5 31) or two (n5 16) prior autologous SCT. Thirty
pts were in PR (n5 26) or CR (n5 4) at the time of SCT and 20 pts
had stable or progressive disease. RIC consisted of fludarabine and
melphalan (100-140 mg/m2). Disease response was assessed at day
+100; 23 pts achieved CR; 17 PR, 7 died and 3 have already pro-
gressed by day +100. With a median follow-up of 6.4 years (range,
5-7.9 years), 16 pts are alive and 34 have died; 13 had NRM (cumu-
lative incidence 26%) and 21 died of relapse. The median survival is
2.3 years and the estimated 7-year overall and progression-free sur-
vival (PFS) rates were 34% (95 C.I. 21-47%) and 26% (95 C.I. 14-
38%), respectively. The PFS curve showed an apparent plateau after
3 years, with no later relapses, suggesting a potential cure. In multi-
variate analysis, adverse prognostic factors for survival included SCT
not in remission, long duration of disease and SCT from a female do-
nor to a male recipient. Related and unrelated donor SCT had a sim-
ilar outcome. The 7 year PFS in 19 pts with none of these adverse
factors was 47%. Chronic GVHD and achievement of CR after
SCTwere associated with improved outcome. In conclusion, alloge-
neic SCT can result in long-term PFS in a subset of MM pts failing
prior therapy and should be considered early after failure and prefer-
ably after achieving a response with salvage therapy. The treatment
goal is to achieve a CR as this is associated with better outcome.
